Search hospitals

>

New York

>

Rochester

University of Rochester Medical Center

Claim this profile

Rochester, New York 14618

Global Leader in HIV Infection

Global Leader in Human Immunodeficiency Virus Infection

Conducts research for AIDS

Conducts research for Cancer

Conducts research for Alzheimer's Disease

762 reported clinical trials

45 medical researchers

Photo of University of Rochester Medical Center in RochesterPhoto of University of Rochester Medical Center in RochesterPhoto of University of Rochester Medical Center in Rochester

Summary

University of Rochester Medical Center is a medical facility located in Rochester, New York. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Cancer, Alzheimer's Disease and other specialties. University of Rochester Medical Center is involved with conducting 762 clinical trials across 864 conditions. There are 45 research doctors associated with this hospital, such as Richard G. Moore, Brea Lipe, MD, Anton Porsteinsson, MD, and Daniel Lachant.

Top PIs

Clinical Trials running at University of Rochester Medical Center

Breast Cancer

Facioscapulohumeral muscular dystrophy

Cancer

Acute Myelogenous Leukemia

Acute Myeloid Leukemia

Facioscapulohumeral Muscular Dystrophy

Heart Failure

Multiple Sclerosis

Bladder Cancer

Multiple Myeloma

Image of trial facility.

Neratinib + Endocrine Therapy + Trastuzumab

for Breast Cancer

This trial involves treating breast cancer patients with three drugs: neratinib, an aromatase inhibitor, and trastuzumab. These drugs work together to block cancer growth signals, lower estrogen levels, and help the immune system attack cancer cells. The treatment is aimed at patients with HER2-positive breast cancer who may not respond well to standard treatments. Trastuzumab is a well-established treatment for HER2-positive breast cancer, often used in combination with other therapies.

Recruiting

1 award

Phase 2

16 criteria

Image of trial facility.

Alisertib + Endocrine Therapy

for Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy.

Recruiting

1 award

Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Rochester Medical Center?

Where is University of Rochester Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Rochester Medical Center accept?

What awards or recognition has University of Rochester Medical Center received?